News Releases

For the first time, Penn Medicine researchers used lab-grown organoids created from tumors of individuals with glioblastoma to accurately model a patient’s response to CAR T cell therapy in real time.

A simple dietary supplement may provide a new, cost-effective approach to boost CAR T cell function, according to early findings shared at the ASH Annual Meeting.

Penn Medicine has partnered with Mark Cuban's Cost Plus Drug Company through its innovative Cost Plus Marketplace in a strategic alliance that will allow Penn Medicine to secure the top 100 most frequently dispensed generic drugs from the company.

Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in blood cancer and benign hematology research at the ASH Annual Meeting 2024.

After the COVID-19 pandemic struck, online reviews of health care facilities dropped significantly, and they have not yet fully recovered, according to a new analysis led by researchers at the Perelman School of Medicine.

The plan outlines an ambitious roadmap to become the nation’s most eco-friendly health care organization.

Findings include policy considerations for lawmakers to consider as a new Congress takes shape.